Patent · US Active

Phospho-specific anti-Pax3 antibodies

US8304521B2 · kind B2 · utility

1Cited by
1References
11Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJun 3, 2009
Grant dateNov 6, 2012
Priority date
Expiry dateMar 2, 2030

Classification

  • Technology area (CPC G)Physics
  • CPC primaryG01N2500/10
  • WIPO fieldMeasurement
  • WIPO sectorInstruments

Abstract

Pax3, a member of the paired class homeodomain family of transcription factors and an essential protein for early skeletal muscle development, was shown to be phosphorylated in proliferating mouse primary myoblasts. Furthermore, Ser205, Ser201 and Ser209 were identified as the only sites of phosphorylation on Pax3 in proliferating mouse primary myoblasts. Phosphorylation of Ser205 was shown to be required for the efficient phosphorylation of Ser201 and/or Ser209. Site-specific antibodies were made to each of these three sites when phosphorylated. These three sites are also present and phosphorylated in the Pax3-FOXO1 fusion protein, and phosphorylation of these sites may play a role in ARMS. Thus, these new antibodies may be used in studying the regulation of nerve and muscle development and differentiation and in finding therapeutic solutions for certain disorders, including Waardenburg syndrome and childhood solid muscle tumor alveolar rhabdomyosarcoma (ARMS).

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.